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Dietary fat is the most concentrated source of
energy for organism as 1 g of fat provides 9 kcal of
energy. It is also the carrier of fat-soluble vitamins
and essential fatty acids. Liver plays an important
role in the metabolism of lipids. It produces the bile,
which facilitates the digestion and intestinal absorp-
tion of lipids. The synthesis and oxidation of fatty
acids take place in liver. Formation of ketone bodies
from fatty acids also occurs in liver. Moreover this
organ integrates the synthesis and metabolism of
plasma lipoproteins. Desaturases are the enzymes
which are involved in transformation of fatty acids.
They can insert the double bonds into different posi-
tions of fatty acids (∆4, ∆5, ∆6, ∆9) but not higher
than ∆9, and that is why linoleic (LA) and α-
linolenic (ALA) essential fatty acids should be sup-
plied with diet (1). 
Breast cancer is the most frequent type of can-
cer among women and the third in global popula-
tion. Numerous nutritional factors are associated
with elevated or reduced risk of this type of cancer
(2, 3). Despite the fact that the etiology of most
cases of this disease is unknown (4), quantity and
quality of fat, especially the fatty acids ratio in diet,
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Abstract: The aim of this study was to assess the influence of diet supplementation of pregnant and breast-
feeding female Sprague-Dawley rats with conjugated linoleic acids (CLA) on the ∆6- and ∆5-desaturase activ-
ity in hepatic microsomes as well as on fatty acids profile and lipids peroxidation in liver and hepatic micro-
somes of the progeny with chemically induced mammary tumors. Rats were divided into two groups with dif-
ferent diet supplementation (vegetable oil (which did not contain CLA) or CLA). Their female offspring was
divided within these groups into two subgroups: (1) ñ fed the same diet as mothers (K1 ñ oil, O1 ñ CLA), and
(2) ñ fed the standard fodder (K2, O2). At 50th day of life, the progeny obtained carcinogenic agent (7,12-
dimethylbenz[a]anthracene). Higher supply of CLA in diet of mothers resulted in lower susceptibility to chem-
ically induced mammary tumors in their offspring (p = 0.0322). It also influenced the fatty acids profile in liv-
ers and in hepatic microsomes, especially polyunsaturated n3 and n6 fatty acids. CLA inhibited the activity of
the desaturases, which confirmed that CLA can reduce the level of arachidonic acid directly, reducing linoleic
acid content in membranes, or indirectly, through the regulation of its metabolism. We were unable to confirm
or deny the antioxidative properties of CLA. Our results indicate that the higher supply of CLA in mothersí diet
during pregnancy and breastfeeding causes their incorporation into tissues of children, changes the efficiency
of fatty acids metabolism and exerts health-promoting effect in their adult life reducing the breast cancer risk.
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Abbreviations: AA ñ arachidonic acid, ALA ñ α-linoleic acid, CLA ñ conjugated linoleic acids, D5D ñ ∆5-
desaturase, D6D ñ ∆6-desaturase, DHA ñ docosahexaenoic acid, DMBA ñ 7,12-dimethylbenz[a]anthracene,
EPA ñ eicosapentaenoic acid, FA ñ fatty acids, FAME ñ fatty acids methyl esters, LA ñ linoleic acid, MDA ñ
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are associated with many cancers (e.g., breast,
colon) (3). 
Conjugated linoleic acids (CLA) are a group of
positional and geometric isomers of linoleic acid
which contain two conjugated double bonds in their
chain. They occur especially in milk, dairy products
and meat from ruminants. These types of food are
the richest dietary sources of CLA. Cis-9, trans-11
octadecadienoic acid (rumenic acid ñ RA) consti-
tutes over 90% of all CLA isomers in dietary prod-
ucts (5). The second important CLA isomer ñ trans-
10, cis-12 octadecadienoic acid, is present in many
dietary supplements (6). Despite the fact, that
rumenic acid can be endogenously synthesized from
trans-11 octadecenoic acid (vaccenic acid ñ VA) by
the action of ∆9-desaturase, dietary intake is the
main source of CLA for people (7). Results of sci-
entific research show the positive impact of CLA in
different pathological conditions, especially differ-
ent types of cancer, e.g., breast cancer (7ñ9). CLA
are active in each step of cancer development, from
initiation to metastasis. They can reduce the cancer-
ous process risk and there are many possible mech-
anism of this action: antioxidative properties, influ-
ence on eicosanoids synthesis, apoptosis etc. (11).
Polyunsaturated fatty acids have beneficial effect in
many pathological conditions, e.g., in many types of
cancer. The content of unsaturated fatty acids in cel-
lular structures is the result of intake of essential
polyunsaturated fatty acids from diet and their
endogenous synthesis and subsequent utilization in
body building. Elongation and desaturation depend
on both the absolute content of these fatty acids and
the activity of various enzymes, e.g., desaturases,
which control this metabolic pathway. Activity of
∆6- and ∆5-desaturases is the main factor control-
ling the conversion of dietary linoleic acid (LA) to
arachidonic acid (AA). Therefore, in the examina-
tion of fatty acids composition in mammalian tissues
it is essential to take into account not only diet but
also the activity of crucial enzymes. Many dietary
factors can influence this activity (12ñ14).
Table 1. Fatty acids composition of applied diets (% of FA).
Fatty acid Fodder Fodder + oil Fodder + CLA
C6:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C12:0 < 0.1 < 0.1 0.1 ± 0.1
C14:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C15:0 0.1 ± 0.0 0.1 ± 0.0 ñ
C16:0 13.3 ± 0.1 10.5 ± 0.1 11.2 ± 0.2
C16:1 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C17:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C18:0 2.7 ± 0.0 2.5 ± 0.0 2.5 ± 0.0
C18:1 n9 cis 16.6 ± 0.1 34.5 ± 0.1 15.9 ± 0.2
C18:2 n6 cis 40.5 ± 0.1 35.1 ± 0.1 31.5 ± 0.3
C18:3 n3 22.7 ± 0.1 14.1 ± 0.0 16.7 ± 0.2
C20:0 0.2 ± 0.0 0.2 ± 0.1 ñ
cis-9, trans-11 CLA ñ ñ 8.6 ± 0.3
trans-10, cis-12 CLA ñ ñ 8.5 ± 0.4
C20:1 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
C21:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C20:2 ñ ñ 0.1 ± 0.0
C22:0 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.0
C20:5 n3 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C22:2 0.2 ± 0.0 0.1 ± 0.0 ñ
C23:0 ñ ñ 0.1 ± 0.0
C24:0 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0
C24:1 < 0.1 0.1 ± 0.0 ñ
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The aim of this study was to assess the influ-
ence of diet supplementation of pregnant and breast-
feeding female Sprague-Dawley rats with conjugat-
ed linoleic acids on thiobarbituric acid reactive sub-
stances (TBARS) concentration and fatty acids pro-
file in the liver and hepatic microsomes as well as on
the ∆6- and ∆5-desaturase (E.C. 1.14.19.) activity in
hepatic microsomes of the progeny with chemically
induced mammary tumors. 
EXPERIMENTAL
Animals
This research and guiding principles in the care
and use of laboratory animals were approved by The
Local Ethical Committee on Animal Experiments.
The whole experiment was thoroughly described
previously (15). Briefly, maiden adult female
Sprague-Dawley rats (n = 8), which came from
Division of Experimental Animals, Department of
General and Experimental Pathology (Medical
University of Warsaw, Warszawa, Poland), after 1-
week adaptation period were randomly divided into
two groups of 4 each. Each group had a different
dietary supplementation: group K received veg-
etable oil whereas group O ñ Bio-CLA (Pharma
Nord, Vojens, Denmark) given intragastrically in
the amount 0.15 mL per day, which corresponds to
100 mg of CLA. Applied vegetable oil, purchased
from the Pharma Nord, did not contain the CLA and
was a substrate for the CLA synthesis. Detailed
composition of fatty acids of applied oil was: C16:0
(5.7 ± 0.0)%, C18:0 (0.4 ± 0.0)%, C18:1 n9 (64.5 ±
0.1)%, C18:2 n6 (25.5 ± 0.0)%, C20:04 n6 (0.3 ±
0.0)% C24:1 (0.2 ± 0.0)%. Supplementation lasted
for the whole period of pregnancy and breastfeed-
ing. The female offspring was separated from their
mothers at the 30th day of age and within each
group of supplementation was divided into two sub-
groups of 8ñ10 individuals each: 1 ñ with diet
enriched with the same dietary supplement that had
been previously given to their mothers (group K1
obtained vegetable oil and group O1 ñ Bio-C.L.A.
and 2 ñ fed exclusively the standard Labofeed H
fodder H (fodder producer ìMorawskiî, Øurawia 19,
Kcynia, Poland). Table 1 shows the fatty acids com-
position of applied diets. Dietary supplementation of
subgroups was conducted for the following 21
weeks from 30 days of life. The offspring received
via gavage at 50th day of life a single dose of 80.00
mg/kg body weight of carcinogenic agent ñ DMBA
(7,12-dimethylbenz[a]anthracene, approx. 95%,
Sigma-Aldrich, Saint Louis, Missouri, USA) for the
induction of mammary tumors. Rats were weighed
and palpated weekly to detect the appearance of
mammary tumors. The animals were decapitated
and exsanguinated, and livers and tumors were col-
lected. Isolated tumors were histopathologically
evaluated as adenocarcinomas and papillary adeno-
carcinomas of mammary gland. Spontaneous tumors
were not found in maternal rats during the whole
experiment.
Preparation of experimental material
Samples of liver were collected during necrop-
sy and stored at ñ70OC before the analysis.
Hepatic microsomes were prepared immediate-
ly after decapitation according to the slightly modi-
fied method of K≥yszejko-Stefanowicz (16). A sam-
ple of liver (4 g) was mechanically homogenized in
saccharose solution (16 mL; 0.25 mol/L) buffered
with Tris-buffer (pH 7.4). The obtained homogenate
was centrifuged three times: (1) for 10 min at 1000
◊ g at 4OC, (2) for 20 min at 16000 ◊ g at 4OC, and
(3) for 75 min at 100000 ◊ g at 4OC. The applied
modification refers to the fact, that as we were inter-
ested only in microsomal fraction, each time the sed-
iment was discarded and the supernatant was again
centrifuged with increasing speed. Final pellet was
resuspended in 4 mL 0.25 mol/L saccharose solution
and obtained suspension of hepatic microsomes was
stored at ñ70OC until further analysis.
Fatty acids analysis
Fatty acid analysis was made with gas chro-
matography (GC) using gas chromatograph (GC-
17A gas chromatograph, Shimadzu, Kyoto, Japan)
with capillary column (BPX 70; 60 m ◊ 0.25 mm
i.d., film thickness 0.20 µm, SGE, Ringwood,
Australia) and flame-ionization detection. 
Samples of liver were thawed only once and
three parallel samples of 0.2 g were taken for lipids
extraction according to Folch et al. with slight mod-
ification (17). Applied modification refers to the
volume and sequence of organic solvents, which
were used in extraction procedure. Fatty acids
methyl esters (FAME) were prepared according to
procedure of Bondia-Pons et al. (18) with slight
modifications, which were thoroughly described
elsewhere (19). 
The hepatic microsomes were thawed only
once and three parallel samples of 200 µL of micro-
somal suspensions were taken for lipids extraction.
Lipids were extracted according to Folch et al. with
slight modification (17). Briefly, a sample of micro-
somal suspension was mixed with 2.5 mL of chloro-
form : methanol (2 : 1, v/v) and after vigorous shak-
ing the chloroform layer was separated. The residue
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was mixed with 1.5 mL of chloroform : methanol (2
: 1, v/v) and the extraction was repeated. Combined
chloroform layers were centrifuged for 10 min at
1000 ◊ g and the sediment was discarded. The organ-
ic extract was evaporated under stream of nitrogen
and the residue was taken for the preparation of
FAME according to procedure of Bondia-Pons et al.
(18) with slight modifications, which was also used
for liver samples. The detailed procedure of FAME
analysis was previously described and applied modi-
fication refers to the volumes of solvents (19).
TBARS analysis
Samples of liver were thawed only once and
sample of 0.5 g was taken for TBARS analysis with
spectrophotometric method (20). This sample was
mechanically homogenized with teflon homogeniz-
er in 2.5 mL of sodium chloride solution (0.9%).
Afterwards, 2.5 mL of phosphate buffer (pH 7.0)
and 1.5 mL of trichloroacetic acid (1.7 mol/L), were
added to 0.5 mL of previously obtained
homogenate. The whole sample was shaken vigor-
ously and centrifuged for 15 min at 1000 ◊ g at 0OC,
to separate the protein sediment. The 1.0 mL of 2-
thiobarbituric acid solution (69 mmol/L) was added
to 3.0 mL of supernatant; the whole sample was
shaken vigorously and heated for 15 min on boiling
water bath. The absorbance was measured at λ = 530
nm after cooling to room temperature. The reference
sample was prepared analogously with 0.5 mL of
sodium chloride solution (0.9%). Three parallel
samples were prepared for each liver sample.
Enzymes activity analysis
Enzymes activity was determined in an indi-
rect way because the amount of AA formed in vitro
from LA correlates with the activity of the investi-
gated enzymes (21). The measurement of these
activities was carried out according to previously
published method (22), with slight modifications.
We decided not to use the radioisotopes, which
were applied in original procedure. Each 1.0 mL
reaction mixture contained 5 mmol ATP, 0.1 mmol
CoA, 1.25 mmol NADH, 0.5 mmol niacinamide,
2.25 mmol glutathione and 5 mmol MgCl2, dis-
solved in phosphate buffer pH 7.4 and 200 nmol
sodium salt linoleic acid. The reaction mixture was
preincubated for 5 min at 37OC. The enzymatic
reaction was started by the addition of 0.2 mL of
hepatic microsomes suspension. The whole mixture
was incubated in a shaking water bath for 90 min at
37OC. Further analytical procedure consisted of
lipids extraction according to Folch et al. (17) and
esterification (22). 
The fatty acids concentrations in samples were
determined with high performance liquid chro-
matography (HPLC) with UV/VIS detection (Merck
Hitachi, L-7100 pump, UV/VIS L-74200 detector,
CTO-10 AS oven, YMC-Pack ODS-AM S-5 µm
column, the column temp. 30OC, λ = 198 nm). The
activity index of ∆6-desaturase (D6D) was calculat-
ed as the ratio of γ-linolenic acid (GLA) concentra-
tion to linoleic acid (LA) concentration and the
activity index of ∆5-desaturase (D5D) was
expressed as the ratio of arachidonic acid (AA) con-
centration to dihomo-γ-linolenic acid (DGLA) con-
centration in liver microsomes. The content of AA
in liver microsomes was calculated in protein con-
tent, determined using the method of Lowry et al.
(23). The differences in AA concentrations between
incubated and non-incubated samples indicate the
activity of investigated enzymes.
Table 2. Characterization of experimental groups.
Group K1 K2 O1 O2
(number of individuals) (n = 10) (n = 9) (n = 8) (n = 9)
Mothersí diet
Lab. H Lab. H Lab. H Lab. H
+ oil + oil + CLA + CLA
Progenyís diet 
Lab. H 
Lab. H
Lab. H
Lab. H
+ oil + CLA
Number of individuals with tumors 8 7 2 3
Age of first tumor appearance
[week]
19 17 15 21
Total number of tumors 14 11 4 5
Maximal number of tumors per individual 0ñ3 0ñ4 0ñ3 0ñ2
Maximal weight of tumors per individual
[g]
31.77 16.19 11.81 4.27
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Statistical analysis 
All data are shown as the mean values ± stan-
dard deviation. For variables with skew distribution,
obtained data were transformed into logarithms and
retransformed after calculations. They are presented
as the mean and confidence interval. Results
obtained for fatty acids and TBARS content were
evaluated with Statistica 10.0 (StatSoft, KrakÛw,
Poland). Due to the relatively small number of indi-
viduals in each group, the data were tested with
Kruskal-Wallis test and p-value ≤ 0.05 was consid-
ered significant. 
Results of enzymes activity were evaluated
with statistical methods such as: PCA (principal
component analysis), ANOVA with permutation
test and ASCA (analysis of variance-simultaneous
component analysis).
RESULTS 
All four groups of the progeny received
DMBA administered intragastrically in a single dose
of 80 mg/kg body weight and the breast tumors,
identified as adenocarcinomas and papillary adeno-
carcinomas of mammary gland, appeared in all
investigated groups. The characterization of experi-
mental groups, as well as the effectiveness of cancer
induction are shown in Table 2. CLA decreased the
incidence of mammary cancer in investigated ani-
mals (p = 0.0322). Moreover, the tumorsí number
and weight were smaller than in two oil groups. In
O1 breast tumors appeared much earlier (on average
at 15th week of life) than in other groups, but their
number per individual was the smallest. We
observed strong cancer preventive properties of
CLA also in O2 group, where both the number and
mass of tumors were similar to those in O1, which
suggests that dietary intake of CLA from the very
early period of life is very important for reducing the
risk of carcinogenesis (15). 
Comparison of average mass of livers revealed
that applied supplementation significantly influ-
enced their weight (Table 3). We observed the high-
est mass of livers obtained from animals from K1,
whereas the mass of these organs from K2 was the
smallest. Two-step supplementation with CLA
seems not to affect the weight of examined organs,
as their mass was slightly lower than in K1 but
slightly higher in O2 and K2. 
We compared the fat content in livers from
examined groups. There were significant differences
in amount of fat among them (Table 3). The highest
content of fat occurred in livers from K2, whereas its
content in both CLA groups was lower. Mean con-
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tent of fat in O2 was the lowest but we observed sig-
nificant variations among individuals. No connec-
tion was found between liver mass and its fat con-
tent in examined groups. 
Concentration of TBARS, in respect both to
the mass of in liver tissue and to in its fat content,
did not differed among examined groups. Moreover,
in all groups great differences among individuals
were observed, which suggests that the influence of
applied dietary supplementation on the oxidative
stress is marginal. 
FAME profiles of livers were measured using
gas chromatography (GC). In our experiment we
analyzed 31 fatty acids. C18:0, C20:4 n6 (AA),
C16:0, C18:2 n6 cis (LA), and C22:6 n3 (DHA)
were found to be the main fatty acids in livers of all
investigated groups (Table 4). There were signifi-
cant differences in concentration of some fatty acids
among examined groups. Those differences were
caused mainly by two-step supplementation of diet
with conjugated linoleic acids. In O1 we detected
the highest concentration of C18:0, C20:1, AA and
DHA acid and the lowest concentration of C16:0,
C16:1, C18:1 n9 cis (OL), C18:2 n6 trans, LA,
C18:3 n3 (ALA), C20:2 and C24:1 acids. The two-
step supplementation of diet with vegetable oil
increased the mean concentration of C21:0 and
decreased the concentration of C20:1 in livers of K1
group. Unlimited consumption of standard fodder
caused visible similarity in content of most fatty
acids in livers of K2 and O2. 
FAME profiles of hepatic microsomes were
also investigated using GC and 29 fatty acids were
identified and determined in them. The most com-
mon fatty acids in microsomes obtained from livers
from animals of all experimental groups were:
C18:0, C20:4 n6 (AA), C16:0, C18:2 n6 cis (LA)
and C22:6 n3 (DHA). The concentration of many of
them differed significantly among experimental
groups (Table 2). Concentration of some of the sat-
urated fatty acids (C14:0, C15:0, C16:0 and C24:0)
was decreased, whereas concentration of others
(C18:0) was increased by the two-step supplementa-
tion of diet with CLA. In microsomes of O1 group
we also detected the lowest concentration of C16:1,
OL, LA, ALA and C24:1 and the highest concentra-
tion of C20:1, C20:3 n3 and DHA. The two-step
supplementation of diet with vegetable oil had also
great influence on fatty acids concentration in hepat-
ic microsomes and it increased concentration of
some fatty acids (C14:0, OL, C21:0, C20:2, EPA,
C24:0) and decreased the AA content. 
In our experiment, we used Bio-C.L.A. as a
source of CLA. As previously described, it consists
of several fatty acids, mostly trans-10, cis-12 CLA
(33%) and cis-9, trans-11 CLA (31%) (18). These
two main CLA isomers were detected only in all liv-
ers of O1 group. In livers acquired from other inves-
tigated groups only rumenic acid (RA) was present,
but in much lower amount. In O1 group, with two-
step CLA supplementation, the percentage share of
RA in total fatty acids amount in liver was much
higher than in other groups (Table 4) and its mean
content was 0.2 ± 0.1% of total fatty acids. The other
CLA isomer: trans-10, cis-12 CLA constituted only
0.1 ± 0.0% of total fatty acids in livers. In microso-
mal fraction of hepatic tissue both CLA isomers
were identified only in O1 group (Table 5).
Comparison of their distribution in hepatic micro-
somes revealed the great similarity to their distribu-
tion in whole tissue, because cis-9, trans-11 CLA
concentration tended to be much higher than trans-
10, cis-12 CLA (0.2 ± 0.0% versus 0.1 ± 0.0%).
Our experiment allowed to test the statistical
differences in dietary supplementation and the dif-
ferences in supplements administration to mothers
and children (K1, O1) or only to mothers (K2, O2)
on parameters describing the desaturation effective-
ness. Results of permutation test for individual
effects and their interactions are shown in Figure 1.
Results of the analysis of the main factors and
interactions are shown in Figure 2.
In applied model systems the differences in
arachidonic acid concentrations between incubated
and non-incubated samples indicated the enzymesí
activity. The highest enzymes activity was found in
K1 group, which proves that the addition of veg-
etable oil increases the levels of AA and increases
the activity of D6D. If supplementation is carried
out only for mothers (K2), this effect is less pro-
nounced. In case of CLA supplementation, the
observed effect was opposite (Table 6). 
Two-step supplementation of diet with veg-
etable oil caused the increase in AA concentration,
whereas the effect of two-step supplementation with
CLA was opposite. If the supplementation was lim-
ited only to mothers, CLA increased AA concentra-
tion, whereas oil decreased it. 
DISCUSSION AND CONCLUSION
The liver is a key organ in lipids metabolism. It
integrates the pathways of fatty acids, triacylglyc-
erols and phospholipids synthesis and degradation.
Many processes of lipid metabolism, e.g., fatty acids
esterification or desaturation, are related to microso-
mal fraction of cells where necessary enzymes are
located (24) and therefore liver is an appropriate
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organ to investigate the profile of CLA and other
fatty acids (25).
Conjugated linoleic acids are a group of iso-
mers of linoleic acid with wide range of biological
activity. Their beneficial properties in many patho-
logical conditions e.g., obesity, arteriosclerosis, car-
diovascular diseases, osteoporosis, diabetes, insulin
resistance, inflammation and different types of can-
cer are the subject of numerous scientific studies.
Their ability to lower the breast cancer risk draws
especially much attention. Many potential mecha-
nisms of anticancer activity of CLA are investigat-
ed, e.g., antiproliferative, proapoptotic, antiangio-
genic, antiestrogenic and competition with linoleic
acid in metabolic pathway (11). Activity of ∆6- and
∆5-desaturases is the main factor which controls the
conversion of LA to AA, however the effectiveness
of this reactions depends not only on the activity of
crucial enzymes but also on the absolute content of
fatty acids, as the substrates. Since many dietary fac-
tors can regulate this pathway, we decided to check
whether CLA can influence these enzymes, directly
and indirectly. It seems to be especially important in
cancerous process. As rats show gender differences,
with females responding better than males (26), in
our study we used female Sprague-Dawley rats as
model organisms. We previously showed that sup-
plementation of diet with 1.0% CLA not only
decreases the risk of chemically induced breast can-
cer in female Sprague-Dawley rats but also influ-
ences the fatty acids profile in serum and in hepatic
microsomes (19). In this study, we decided to use
one or two step supplementation of diet to verify if
the overall dose of CLA and the time of supplemen-
tation influenced the effectiveness of chemopreven-
tive action. 
Addition of CLA to the diet of pregnant and
breastfeeding rats increases their concentration in
maternal milk and as a consequence ñ their intake by
the offspring (27, 28). The same correlation was
shown for women who consumed dietary products
enriched with CLA. Their milk contained much
more CLA (29). We also previously proved that
numerous dietary and environmental factors can ele-
vate CLA content in maternal milk of breastfeeding
women (30, 31). In our experiment, the higher sup-
ply of conjugated linoleic acids in diet of pregnant
and breastfeeding females revealed the lower sus-
ceptibility to chemically induced mammary tumors
in their offspring (Table 2). Effectiveness of chemo-
Figure 1. Results of permutation test for the various effects
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preventive action was comparable in both CLA
groups (O1 and O2), which suggests that optimal
dosage of conjugated diens of linoleic acid in early
stage of life influences health in adulthood. Our
results are in line with those of Ip et al. (32), who
supplemented the diet of young rats for 5 weeks
before the carcinogenic agent administration and
demonstrated the inhibition of mammary carcino-
genesis. They claimed that CLA given during the
maturation of mammary glands can change their
structure, e.g., diminish the number and differentia-
tion of terminal end buds and can reduce the number
of places of potential cancer induction. Moreover,
numerous studies confirm the anticancerogenic
properties of CLA in breast cancer model (9, 33,
34). 
We observed significant differences in liver
mass among examined groups. Feeding vegetable
oil during the whole life resulted in increase in the
liver weights, whereas influence of two-step CLA
supplementation seemed to be similar but not so
evident. Our observations are in line with those
obtained by others. Javadi et al. (35) detected an
increase in liver weights only after 12 weeks of
feeding mice with CLA, but there were no differ-
ences after 3 weeks period. Akahosi et al. (36) did
not observe any significant differences in inner
organs weight, however, mass of livers seemed to be
slightly bigger in groups of male Sprague-Dawley
rats supplemented with single CLA isomers, or with
their mixture. Ip et al. (9) did not note any differ-
ences in organsí mass either when the mixture of
CLA isomers was applied. Long term feeding of
male Fisher rats with 1.0% of CLA mixture did not
change the liver weights (26). Turpeinen et al. (37),
who applied single CLA isomer ñ cis-9, trans-11,
claimed that rumenic acid did not influence the inner
organsí mass. These findings are in line with those
of Ip et al. (38), who used in their experiment mice
with cancer, and observed that trans-10, cis-12 CLA
but not cis-9, trans-11 CLA caused the significant
increase of mass of such organs as liver, heart and
spleen. 
As far as fatty acids profile in liver is con-
cerned, our observations were similar to those of
other authors. Javadi et al. (35) found the same fatty
acids to be the most prominent in mice livers and
confirmed that both CLA supplementation and the
feeding period significantly changed the content of
some of the fatty acids in examined tissue. Twelve
weeks supplementation reduced the concentration of
AA, 22:4 n6, C20:3 n6 and DHA, and elevated the
content of C18:4 n3, C20:1 n9 and EPA. Moreover,
the addition of CLA to diet changed the amount of
C16:0, C18:3 n6, C20:2 n6 and C22:5 n3. The
authors concluded that these changes could be the
result of lower effectiveness of desaturation and
elongation processes, caused by CLA. Also
Kostogrys et al. (39), who checked whether CLA
can reverse the harmful effect of high-fructose diet
on fatty acids profile in liver, emphasized the bene-
ficial impact of CLA on the concentration of some
of the fatty acids.
As far as fatty acids concentration in microso-
mal fraction of livers are concerned, we detected the
highest amounts of the same fatty acids as other
researchers did (40ñ42). They proved that fatty
acids profile in liver microsomes depended on the
fatty acids profile in diet and dietary supplementa-
tion, especially with long chain polyunsaturated
fatty acids, significantly influence not only the fatty
acids composition of microsomes but also their
function, e.g., activity of numerous enzymes. 
We observed some interesting tendencies in
fatty acids content, especially in n3 and n6 polyun-
saturated fatty acids. The highest content of DHA
and its substrate ALA was detected in O1, whereas
their lowest content was in O2. For EPA, which is
the intermediate in conversion of ALA to DHA (43),
a similar result might be expected. However, we did
not detect such correlation, but obtained results con-
firm our previous observation. CLA seem to
Table 6. Influence of the diet on AA concentration increase, D6D and D5D activity in hepatic microsomes.
Increase of AA
Group  concentration D6D D5D
[mg/100 mg of protein]  
K1 0.43 ± 0.13 (4.39 ± 0.17) ◊ 10-3 1.73 ± 0.06  
K2 0.13 ± 0.07 (4.38 ± 0.11) ◊ 10-3 1.71 ± 0.08  
O1 0.16 ± 0.06 (2.41 ± 0.22) ◊ 10-3 1.68 ± 0.12  
O2 0.13 ± 0.08 (2.71 ± 0.15) ◊ 10-3 1.71 ± 0.07  
All data are shown as the mean values ± standard deviation.
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increase DHA and decrease ALA and EPA content
in hepatic microsomes (19). Cao et al. (28) also
observed elevated levels of DHA in liver phospho-
lipids of suckling rats after supplementation of their
mothersí diet with CLA. Also Martins et al. (25)
detected similar increase in DHA content both in
polar and in neutral lipids of ratsí livers after CLA
mixture administration, while single isomers did not
exert such an effect. Eder et al. (44) observed ele-
vated levels of DHA as well as the sum of n-3 FA in
liver phospholipids as a result of CLA supplementa-
tion.
LA, which starts the n6 fatty acids family, is
converted into AA, which in turn is the precursor for
eicosanoids synthesis. The highest concentration of
AA was detected in O1, whereas its lowest amount
was in K1. These results are in line with those for
LA content in microsomes, which was the highest in
K1 and the lowest in O1. It confirms that supple-
mentation of diet with CLA influences the fatty
acids profile in hepatic microsomes, especially
polyunsaturated n6 fatty acids. Belury et al. (45),
who detected the decreased content of LA and AA
in liver phospholipids in mice receiving CLA, also
proved that CLA can compete with n6 fatty acids
and determine their metabolism. Results of Javadi et
al. (35) also confirm the ability of CLA to decrease
the LA and AA content in livers of mice. Some dif-
ferences in our results concerning fatty acids pro-
files in hepatic tissue and its microsomal fraction
after CLA supplementation in relation to results
obtained by others can be caused by the coexisting
cancerous process. Our results indicate that not only
diet but also coexisting factors such as pathological
conditions or diseases e.g., cancers affect the levels
of fatty acids in tissues. We previously reported (19)
the significant differences in fatty acids profile in
serum and hepatic microsomes of rats treated with
DMBA and those not treated with DMBA. It has
been observed that the profile of fatty acids in serum
Figure 2. Results of the analysis of the principal components and their interactions
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of patients suffering from different types of cancer
differs from distribution of fatty acids in wealthy
people. Plasma phospholipids from patients suffer-
ing from bladder cancer contained much lower lev-
els of LA and its metabolites, whereas the levels of
ALA did not differ (46). There are many possible
explanations for this fact but the most probable one
is the changes in lipids metabolism, e.g., enhanced
lipolysis or lipids peroxidation (47) or inhibited
action of desaturases, mainly ∆6- desaturase, which
was characteristic of cancer cells (46). 
Although CLA concentration in breast tissues
is generally higher than in liver (48), phospholipids
of livers are richer in CLA isomers than phospho-
lipids of mammary glands (9). Conjugated linoleic
acids are preferentially incorporated into triacyl-
glycerols rather than into phospholipids (25, 49).
Liver possesses a reasonable ratio between phos-
pholipids and neutral lipids and is an appropriate
organ for studying of CLA incorporation (25). In
this study, we detected both CLA isomers only in
livers and in their microsomal fraction of the O1
group ñ constantly supplemented with CLA. In
other groups only cis-9, trans-11 CLA was present
in examined material, but its concentration was
much lower than in O1. Although the higher supply
of CLA in mothersí diet during pregnancy and
breastfeeding caused only minor incorporation of
CLA into hepatic tissues of children, CLA health-
promoting effects were significant. Trans-10, cis-12
CLA content in hepatic microsomes and liver tissue
was much lower than the content of rumenic acid
despite their similar distribution in fatty acids pool
of O1 group diet (Table 1). Our results are in line
with those of Martins et al. (25), who detected that
cis-9, trans-11 CLA was much more incorporated
into both polar and neutral hepatic lipid fractions
than trans-10, cis-12 CLA. However, Cao et al. (28),
who used equimolar mixture of cis-9, trans-11 and
trans-10, cis-12 CLA in two dosages (1.0 and 2.0%),
found higher concentration of trans-10, cis-12 CLA
isomer in liver phospholipids of both groups and in
phospholipids from livers of their progeny.
According to Tsuzuki (50) such diversity emerges
from differences in metabolism and not in the
bioavailability. Trans-10 cis-12 octadecadienoic
acid activates β-oxidation and facilitates its own
metabolism. Differences in CLA isomers incorpora-
tion are observed not only in liver but also in other
tissues. Huot et al. (51) indicated in caveolae phos-
pholipids of MCF-7 breast cancer cells lower
amounts of trans-10, cis-12 CLA than cis-9, trans-
11 CLA, despite their similar content in applied
mixture. Our previous results also confirmed prefer-
ential incorporation of cis-9, trans-11 CLA into
hepatic microsomes (19) and breast cancer tissues
(15).
Lipid peroxidation is the result of oxidative
stress and can lead to cell and tissue damage (39).
Cancerous process is related to the increase in lipids
peroxidation. Polyunsaturated fatty acids in phos-
pholipids are especially prone to this reaction (52).
Other sources suggest that chemopreventive proper-
ties of PUFA are the result of toxic effect of their
peroxidation products on cancer cells (53). Results
of numerous studies showed the increased levels of
TBARS in serum of patients suffering from cancer
of different organs: breast, lungs, stomach or small
intestine (52, 54). However, some researchers claim
that decreased lipids peroxidation stimulates the
proliferation of cancer cells and promotes their
malignancy (55). Many researches emphasize the
antioxidative properties of CLA. Ha et al. (56) com-
pared the antioxidative potential and concluded that
CLA is as strong an antioxidant as α-tocopherole
and almost as strong as butylhydroxytoluene. We
did not detect any significant changes in TBARS
concentration in livers among examined groups,
which could confirm or deny the antioxidative prop-
erties of CLA. Sugano et al. (57) did not detect any
significant differences in TBARS content in serum
and in hepatic tissue after CLA addition either.
Kostogrys et al. (39), who indicated the elevated
MDA levels in livers after fructose administration,
did not observe any influence of CLA on MDA, in
comparison to control group. Ip et al. (9) also did not
indicate any differences in TBARS content in livers
of animals treated with CLA mixture, although they
observed their decreased amount in mammary
glands. Moreover, the comparison of the strongest
anticancerogenic effect of 1.0% CLA and the
strongest antioxidative action of 0.25% CLA sepa-
rated the toxic effect on cancer cells and the poten-
tial antioxidative properties of CLA. Our results
seem to confirm these findings.
The highest enzyme activities, measured by the
growth of AA, D6D and D5D, was reported in K1
group. Vegetable oil, which was administered to K1,
contained significantly higher amount of LA than
Bio-CLA (almost three times ñ 27%) (19) and
caused the greatest increase in enzyme activity. This
indicates that supplementation of diet with oils rich
in n6 fatty acids stimulates the metabolism of
polyunsaturated fatty acids and formation of AA by
increasing the activity of desaturases. This is turn
may promote the elevated synthesis of eicosanoids,
produced from AA. One of them is prostaglandin E2
(PGE2), which has strong immunosuppressive prop-
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erties and inhibits formation of antibodies and
immune cells. It also shows the pro-inflammatory
and pro-tumorigenic activities (58, 59). The experi-
mental material received from CLA supplemented
animals was characterized by the significantly lower
concentrations of AA and D6D in comparison to
group receiving only vegetable oil. This clearly
shows the inhibitory effect of conjugated linoleic
acid on the activity of the enzymes, that confirms the
assumption that CLA reduces the level of AA in cells
directly by the influence on LA content in mem-
branes, or indirectly, through the regulation of
metabolism. Conjugated linoleic acid can be incor-
porated instead of LA to phospholipids and neutral
fats, which are the part of cell membranes and in this
way reduced the availability of the n6 substrates for
the transition. However, CLA is affecting the metab-
olism of LA, by competing for key enzymes control-
ling transitions of both compounds simultaneously,
which leads to decreased levels of LA metabolites,
including AA and prostaglandins emerging from this
fatty acid. Similar results were obtained by Bretillon
et al. (60), who showed an inhibitory effect of both
CLA isomers: cis-9, trans-11 and trans-10, cis-12
CLA on ∆6-desaturase activity. Thijssen et al. (61) in
the in vivo studies also indicated the reduced activity
of ∆6-desaturase in humans, due to the early supple-
mentation with a mixture of CLA, while CLA had no
effect on ∆5-desaturase activity. Similar results were
obtained in studies with human hepatoma cell line
HepG2, but only for the trans-10, cis-12 CLA (65).
Also Javadi et al. (35) suggest lower desaturation and
elongation activity in the liver of the CLA-fed mice.
Moreover inhibited action of desaturases, mainly ∆6-
desaturase, is characteristic for cancer cells (46).
It is suggested that the desaturase activity
affects the inflammatory process. The increase in
the concentration of AA, which correlates with the
eicosanoids formulation, plays an important role in
the development of inflammation (63). Reduction of
the concentration of AA and its metabolites, leading
to the weakening of the inflammatory response, is
one of the proposed mechanism of anticancerogenic
effect of CLA isomers (64ñ67). 
Our results indicate that conjugated linoleic
acids can inhibit the development of chemically
induced mammary tumors. Their higher concentra-
tion in diet influence the fatty acids profile in livers
and in their microsomal fraction, as well as the
enzymesí activity. The decrease in D6D activity and
the increase in AA concentration due to the presence
of CLA in the diet of animals can confirm their anti-
cancer properties. The higher supply of conjugated
linoleic acid in mothers diet during pregnancy and
breastfeeding not only causes their incorporation
into tissues of children but also exerts health-pro-
moting effect in their adult life. 
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